Jane L. Mendillo

CIK: 0001672424

Transaction Breakdown

Open Market Buys (P)1 (25.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

GENB

Generate Biomedicines, Inc.

Director

LAZ

Lazard, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

GENB
Generate Biomedicines, Inc.
Mar 2, 2026
Purchase(P)
Direct
1.5K shares at avg. $16.00$24K
GENB
Generate Biomedicines, Inc.
Feb 26, 2026
Award(A)
Stock Option (Right to Buy)
Direct
29.6K shares-
LAZ
Lazard, Inc.
Feb 18, 2025
Award(A)
Deferred Stock Units
Direct
642 shares-
LAZ
Lazard, Inc.
Nov 15, 2024
Award(A)
Deferred Stock Units
Direct
636 shares-

		Type	Shares	Price		Ownership
Mar 2, 2026	GENB Generate Biomedicines, Inc.	Purchase(P)	1,500	$16.00	$24,000	Direct
Feb 26, 2026	GENB Generate Biomedicines, Inc.	Award(A) Stock Option (Right to Buy)	29,561	-	-	Direct
Feb 18, 2025	LAZ Lazard, Inc.	Award(A) Deferred Stock Units	642	-	-	Direct
Nov 15, 2024	LAZ Lazard, Inc.	Award(A) Deferred Stock Units	636	-	-	Direct

1-4 of 4 transactions

About Mendillo Jane L

Mendillo Jane L (SEC CIK 0001672424) files insider reports with the SEC as Director of Generate Biomedicines, Inc. (GENB) and Director of Lazard, Inc. (LAZ).

Signal8 holds 4 ownership filings by Mendillo Jane L (1 Form 3, 3 Form 4), filed between Nov 19, 2024 and Mar 2, 2026. Those filings report 4 transactions, from Nov 15, 2024 to Mar 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Mendillo Jane L's filings is in SOMERVILLE, MA.

Recent filings by Mendillo Jane L

Mar 2, 2026: Open-market purchase of GENB shares (Form 4, code P).
Feb 26, 2026: Grant or award of GENB derivative securities (Form 4, code A).
Feb 18, 2025: Grant or award of LAZ derivative securities (Form 4, code A).
Nov 15, 2024: Grant or award of LAZ derivative securities (Form 4, code A).

Other insiders filing for Generate Biomedicines, Inc. (GENB)

ARNOLD FRANCES, Director
Pioneering Medicines 02, LLC, 10% Owner
Nally Michael, Chief Executive Officer
Vessey Rupert, Director
Grous Beth, Chief People Officer
Lee Laurie Anne, Chief Medical Officer

How to read Form 4 transaction codes